A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous NSCLC with documented primary EGFR Exon 20ins activating mutation. 2) Participant must have measurable disease according to RECIST v1.1. 3) Participant must have ECOG performance status 0 or 1.

You may not be eligible for this study if the following are true:

  • 1) Participant has received any prior systemic treatment for locally advanced or metastatic disease. 2) Lack of disease response was documented (radiographically) by an increase in tumor burden. 3) Associated toxicities have resolved to baseline.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.